Observational studyCancer medicine2021

Second- or third-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukemia in general population: Is there a real benefit?

Jim Canet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.